Evaluating nipocalimab for the treatment of chronic inflammatory demyelinating polyneuropathy
Study Overview Nipocalimab, a monoclonal antibody targeting the neonatal Fc receptor (FcRn), has been investigated for its potential therapeutic benefits […]
